PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14712887-1	2003	This study aims to assess the efficacy and tolerance of the metabolic antianginal agent trimetazidine, a 3-KAT inhibitor, in 141 stable angina patients aged 65-86 years.	Trimetazidine	88-101	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	107-110	
20932648-7	2011	Trimetazidine, a 3-ketoacyl coenzyme A thiolase (3-KAT) inhibitor, shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-KAT, and is used clinically as an effective antianginal agent.	Trimetazidine	0-13	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	51-54	
20932648-7	2011	Trimetazidine, a 3-ketoacyl coenzyme A thiolase (3-KAT) inhibitor, shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-KAT, and is used clinically as an effective antianginal agent.	Trimetazidine	0-13	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	193-196	
12869392-6	2003	This discrepancy with our data can be attributed to the reversible competitive nature of trimetazidine inhibition of LC 3-KAT.	Trimetazidine	89-102	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	122-125	
12869392-7	2003	In the presence of 2.5 micromol/L 3-keto-hexadecanoyl CoA (KHCoA), trimetazidine resulted in a 50% inhibition of LC-3-KAT activity.	Trimetazidine	67-80	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	118-121	
12869392-8	2003	However, the inhibition of LC 3-KAT could be completely reversed by increasing substrate (3-keto-hexadecanoyl CoA, KHCoA) concentrations to 15 micromol/L even at high concentrations of trimetazidine (100 micromol/L).	Trimetazidine	185-198	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	32-35	
12667223-6	2003	Trimetazidine selectively inhibits the fatty acid beta-oxidation enzyme 3-keto-acyl-CoA dehydrogenase (3-KAT), and is devoid of any direct haemodynamic effects.	Trimetazidine	0-13	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	105-108	
12869392-9	2003	The study of MacInnes et al was performed using concentrations of 3K-HCoA in excess of 16 micromol/L, a concentration that would completely overcome 100 micromol/L trimetazidine inhibition of LC 3-KAT.	Trimetazidine	164-177	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	197-200	
12869392-13	2003	Combined with our previous studies, we conclude that trimetazidine inhibition of LC 3-KAT decreases fatty acid oxidation and stimulates glucose oxidation, resulting in an improvement in cardiac function and efficiency after ischemia.	Trimetazidine	53-66	thiosulfate sulfurtransferase like domain containing 1	Homo sapiens	86-89